Quanterix
- Company typePublic
- Founded2007
- HeadquartersBillerica, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
Quanterix firmographics
Firmographics- Name
- Quanterix
- Legal name
- Quanterix Corporation
- Website
- https://lucentdiagnostics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Quanterix industry classification
Industry- Product category
- Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testing
- NAICS
- Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB)
Keywords
Where Quanterix is headquartered
LocationHeadquarters
- HQ city
- Billerica
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Quanterix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Testing Services: Blood-based biomarker tests ordered by healthcare providers and processed at CLIA-certified laboratory in Billerica, MA. Revenue generated through insurance billing and self-pay patient options. Insurance coverage varies by payer; some may cover for patients with cognitive symptoms.
- Provider Portal Services: Electronic portal for requisition, ordering, tracking and reporting of biomarker tests. Providers pay fees as set forth on the portal for test kits and services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Insurance-covered testing for eligible patients |
| Unit Pricing | Pay-as-you-go | Self-pay/cash pay testing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
Quanterix product offering
Product offeringCore offering
Quanterix operates through its Lucent Diagnostics brand to provide blood-based biomarker testing for Alzheimer's disease using its proprietary Simoa (Single Molecule Array) ultra-sensitive detection technology. The company runs a CLIA-certified laboratory that processes biomarker tests ordered by healthcare providers and partners, including LucentAD Complete and LucentAD p-Tau 217 assays. It also partners with pharmaceutical companies and screening services to expand access to early Alzheimer's detection.
Product overview
Quanterix, through its Lucent Diagnostics brand, offers a portfolio of blood-based biomarker tests for Alzheimer's disease assessment powered by Simoa ultra-sensitive technology. The product line includes LucentAD Complete (a multi-analyte panel measuring p-Tau 217, Aß42/40, GFAP, and NfL) and LucentAD p-Tau 217 (a single-biomarker test), both using Simoa technology for biomarker detection at femtogram-level sensitivity.
Differentiator
Problem solved
Functional benefit
Brands
- LucentAD: Blood-based biomarker tests for Alzheimer's disease detection, including LucentAD Complete and LucentAD p-Tau 217 products.
- Simoa
- Simoa HD-X
Products and services
- LucentAD Complete
- LucentAD p-Tau 217
Quantifiable outcome
- 90% sensitivity, 90% specificity, 90% accuracy for LucentAD Complete
- +4 more outcomes
Companies that use Quanterix
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles3 records
Quanterix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Quanterix partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Life Line ScreeningcoreLucent Diagnostics partnered with Life Line Screening to offer non-invasive blood-based biomarker tests nationally. Life Line Screening deploys Lucent's tests through its network of over 15,000 community events annually across Florida, California, and Texas. This collaboration expands access to diagnostic testing outside clinical settings, serving both metropolitan and rural communities and addressing the estimated 7 million Americans living with Alzheimer's.
- Johnson & Johnson Innovative MedicinecoreLucentAD p-Tau 217 leverages Quanterix's ultra-sensitive Simoa technology combined with J&J Innovative Medicine's extensively studied p-Tau 217 antibodies to provide high accuracy with a simplified workflow. This antibody licensing enables the high-performance assay with proven correlation to amyloid pathology.
- Banyan Biomarkers, Inc.coreGFAP biomarker is offered pursuant to a license from Banyan Biomarkers, Inc. Banyan GFAP is a registered trademark of Banyan Biomarkers. This licensing agreement enables the multi-analyte panel in LucentAD Complete.
Scale indicators6 records
Recent moves6 records
Quanterix competitors and assessment
Company assessmentEmerging players
- Bio-Techne: Bio-Techne provides protein biomarker reagents, ELISA kits, and Ella automated immunoassay instruments that partially overlap with Quanterix's research-use offerings. While broader in scope, Bio-Techne serves pharma and academic biomarker research customers similar to Quanterix's research segment.
- SomaLogic: SomaLogic's SomaScan proteomics platform provides ultra-sensitive protein biomarker measurement that partially overlaps with Simoa's research-use applications. Both serve pharma/biotech biomarker discovery and validation, though with different underlying technologies.
Direct peers
- C2N Diagnostics: C2N Diagnostics offers PrecivityAD, a blood-based test for Alzheimer's amyloid pathology that directly competes with LucentAD p-Tau 217 and LucentAD Complete. Both companies target the same provider and patient segments with non-invasive, blood-based alternatives to PET imaging and CSF testing.
- Meso Scale Diagnostics: Meso Scale Diagnostics offers the S-Plex and QuickPlex ultra-sensitive electrochemiluminescence immunoassay platforms that compete with Quanterix's Simoa technology in research and clinical trial biomarker applications. Both target pharma/biotech research customers with high-sensitivity multiplex biomarker detection.
- Fujirebio: Fujirebio's Lumipulse G p-Tau 217/β-Amyloid 1-42 plasma ratio test is a direct competitor in blood-based Alzheimer's diagnostics with FDA breakthrough designation. Both companies leverage immunoassay platforms to deliver plasma-based amyloid pathology assessment for clinical use.
Broad incumbents
- Eli Lilly: Eli Lilly markets Kisunla, an FDA-approved Alzheimer's therapy, and is developing companion blood-based diagnostics that overlap with Quanterix's biomarker testing use cases. While a pharma company, Lilly's diagnostic efforts make it a competitor in AD risk assessment pathways.
- Roche Diagnostics: Roche's Elecsys p-Tau 217 plasma test for Alzheimer's competes with LucentAD on installed immunoassay analyzers in hospital and reference labs globally. Roche offers overlapping biomarker capability as part of its broad diagnostics portfolio, leveraging existing customer relationships and payer contracts.
- Beckman Coulter Diagnostics: Beckman Coulter's DxI and Access immunoassay analyzers serve hospital and reference labs with overlapping biomarker testing capabilities. As a broad diagnostics incumbent, Beckman Coulter represents a channel and capability competitor in clinical lab biomarker testing.
- Siemens Healthineers: Siemens Healthineers offers the ADVIA Centaur and Atellica immunoassay platforms that compete with Quanterix's clinical diagnostic positioning. As a broad incumbent with established hospital lab relationships, Siemens represents a channel competitor in blood-based biomarker testing.
- Abbott Diagnostics: Abbott's Alinity ci series and ARCHITECT immunoassay platforms provide biomarker testing infrastructure that competes broadly with Quanterix's clinical lab services. Abbott's installed base in hospitals globally represents a channel alternative for blood-based Alzheimer's testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Quanterix social profiles
Digital presenceQuanterix compliance and trust
Trust signalCompliance2 records
Quanterix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quanterix leadership team
Management profileNumber of profiles
Profiles3 records
Quanterix subsidiaries and ownership
Company hierarchySubsidiaries2 records
Quanterix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quanterix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quanterix
What does Quanterix do?
Quanterix operates through its Lucent Diagnostics brand to provide blood-based biomarker testing for Alzheimer's disease using its proprietary Simoa (Single Molecule Array) ultra-sensitive detection technology. The company runs a CLIA-certified laboratory that processes biomarker tests ordered by healthcare providers and partners, including LucentAD Complete and LucentAD p-Tau 217 assays. It also partners with pharmaceutical companies and screening services to expand access to early Alzheimer's detection.
Is Quanterix a public or private company?
Quanterix is a public company. It is classified as public and is currently operating.
When was Quanterix founded?
Quanterix was founded in 2007. It employs 251 to 500 people.
Where is Quanterix based?
Quanterix is headquartered in Billerica, United States, in the North America region.
How does Quanterix make money?
Two revenue lines are on record. Laboratory Testing Services are the primary driver. The others are provider Portal Services.
Who are Quanterix's main competitors?
Emerging players on record are Bio-Techne and SomaLogic. Direct peers are C2N Diagnostics, Meso Scale Diagnostics and Fujirebio. Broad incumbents are Eli Lilly, Roche Diagnostics, Beckman Coulter Diagnostics, Siemens Healthineers and Abbott Diagnostics.
Does Quanterix have an API?
No public API is recorded for Quanterix.
What industry is Quanterix in?
Quanterix's product category is Clinical Diagnostics — Alzheimer's Disease Blood-Based Biomarker Testing. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.